NCT02437279View on ClinicalTrials.gov

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

PHASE1UnknownINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 24, 2016

Primary Completion Date

June 28, 2018

Study Completion Date

June 30, 2025

Conditions

Stage III Skin Melanoma

Interventions

PROCEDURE

Surgery of the tumor

DRUG

Infusion with ipilimumab 3 mg/kg q3wks

DRUG

Infusion with nivolumab 1 mg/kg q3wks

Trial Locations (1)

1066CX

Netherlands Cancer Institute, Amsterdam

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT02437279 - Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients | Biotech Hunter | Biotech Hunter